Bright Minds Biosciences (DRUG) Earnings Analysis

Bright Minds Biosciences (DRUG) next reports earnings on 2026-08-13, consensus EPS -1.28313 USD. Last quarter (2026-05-20) it beat with EPS -0.8 USD vs -1.05926 USD est (+24.5%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E -31.34.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does DRUG next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-1.28313 USD
Revenue estimaten/a

DRUG earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-20-0.8 USD-1.05926 USD+24.5%Beat
2026-02-12-0.7 USD-0.98 USD+28.6%Beat
2025-12-23-0.41 USD-0.56261 USD+27.1%Beat
2025-08-14-0.53 USD-0.59 USD+10.2%Beat
2025-02-130.01 USD-0.23 USD+104.3%Beat
2024-12-30-0.12 USD-0.44343 USD+72.9%Beat
2024-08-140.04 USDn/an/an/a

Beat rate: 6/6 (100%) over reported quarters with consensus data.

DRUG valuation and analyst view

Trailing P/E-31.34
Trailing EPS-2.86766 USD
Price / book3.31
Dividend yield0.00%
Market cap0.59B
Analyst consensusBuy (4 buy / 0 hold / 0 sell)
Avg price target182.5 USD

Related research pages

Frequently asked questions

When is Bright Minds Biosciences (DRUG)'s next earnings date?

Bright Minds Biosciences is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -1.28313 USD.

Did DRUG beat earnings last quarter?

In its 2026-05-20 report, DRUG posted EPS of -0.8 USD versus a -1.05926 USD estimate — a beat of 24.5%.

What is DRUG's earnings track record?

Over the last 6 reported quarters with consensus data, DRUG beat estimates 6 times (100%).

What is DRUG's current P/E ratio and EPS?

DRUG trades at a trailing P/E of -31.34 on trailing EPS of -2.867663200290474 USD.

What do analysts rate DRUG?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 182.5 USD.